These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 12684909)

  • 41. Short-term entecavir therapy of chronic severe hepatitis B.
    Chen J; Han JH; Liu C; Yu RH; Li FZ; Li QF; Gong GZ
    Hepatobiliary Pancreat Dis Int; 2009 Jun; 8(3):261-6. PubMed ID: 19502165
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Genotype prevalence, viral load and outcome of hepatitis B virus precore mutant infection in stable patients and in patients after liver transplantation.
    Ben-Ari Z; Ashur Y; Daudi N; Shmilovitz-Wiess H; Brown M; Sulkes J; Klein A; Mor E; Tur-Kaspa R; Shouval D
    Clin Transplant; 2004 Aug; 18(4):415-22. PubMed ID: 15233819
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Changes in different regions of hepatitis B virus gene in hepatitis B 'e' antigen-negative patients with chronic hepatitis B: the effect of long-term lamivudine therapy.
    Buti M; Jardi R; Rodriguez-Frias F; Valdes A; Schaper M; Esteban R; Guardia J
    Aliment Pharmacol Ther; 2005 Jun; 21(11):1349-56. PubMed ID: 15932365
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Factors related to the outcome of patients with chronic severe hepatitis B and effectiveness of antivirus therapy].
    Wu YZ; Zhao FL; Zhang CZ; Li MH; Xie Y
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2007 Jun; 21(2):120-2. PubMed ID: 17653310
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The predictive value of liver fibrosis in determining the effectiveness of interferon and lamivudine therapies for chronic hepatitis B.
    Shindo M; Hamada K; Nishioji K; Muramatsu A; Oda Y; Okuno T
    J Gastroenterol; 2004; 39(3):260-7. PubMed ID: 15065004
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Correlation of hepatitis B virus (HBV) genotypes and mutations in basal core promoter/precore with clinical features of chronic HBV infection.
    Du H; Li T; Zhang HY; He ZP; Dong QM; Duan XZ; Zhuang H
    Liver Int; 2007 Mar; 27(2):240-6. PubMed ID: 17311620
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Outcome of lamivudine resistant hepatitis B virus mutant post-liver transplantation on lamivudine monoprophylaxis.
    Chan HL; Chui AK; Lau WY; Chan FK; Hui AY; Rao AR; Wong J; Lai EC; Sung JJ
    Clin Transplant; 2004 Jun; 18(3):295-300. PubMed ID: 15142051
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Basal core promoter, precore region mutations of HBV and their association with e antigen, genotype, and severity of liver disease in patients with chronic hepatitis B in India.
    Chauhan R; Kazim SN; Bhattacharjee J; Sakhuja P; Sarin SK
    J Med Virol; 2006 Aug; 78(8):1047-54. PubMed ID: 16789012
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Profile, spectrum and significance of hepatitis B virus genotypes in chronic HBV-infected patients in Yunnan, China.
    You J; Sriplung H; Chongsuvivatwong V; Geater A; Zhuang L; Huang JH; Chen HY; Yu L; Tang BZ
    Hepatobiliary Pancreat Dis Int; 2008 Jun; 7(3):271-9. PubMed ID: 18522881
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Gene heterogeneity of hepatitis B virus isolates from patients with severe hepatitis B.
    Wu W; Chen Y; Ruan B; Li LJ
    Hepatobiliary Pancreat Dis Int; 2005 Nov; 4(4):530-4. PubMed ID: 16286257
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Favorable efficacy of long-term lamivudine therapy in patients with chronic hepatitis B: an 8-year follow-up study.
    Akuta N; Suzuki F; Suzuki Y; Sezaki H; Hosaka T; Someya T; Kobayashi M; Saitoh S; Arase Y; Ikeda K; Kobayashi M; Kumada H
    J Med Virol; 2005 Apr; 75(4):491-8. PubMed ID: 15714490
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Precore/core promoter mutations and genotypes of hepatitis B virus in chronic hepatitis B patients with fulminant or subfulminant hepatitis.
    Liu CJ; Kao JH; Lai MY; Chen PJ; Chen DS
    J Med Virol; 2004 Apr; 72(4):545-50. PubMed ID: 14981756
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Factors associated with response to lamivudine: Retrospective study in a tertiary care clinic serving patients with chronic hepatitis B.
    Hann HW; Jonsson Funk ML; Rosenberg DM; Davis R
    J Gastroenterol Hepatol; 2005 Mar; 20(3):433-40. PubMed ID: 15740489
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Poor response to 18-month lamivudine monotherapy in chronic hepatitis B patients with IgM anti-HBc and acute exacerbation.
    Chen JJ; Lin CY; Sheu MJ; Kuo HT; Sun CS; Tang LY; Wang SL; Tsai SL
    Aliment Pharmacol Ther; 2006 Jan; 23(1):85-90. PubMed ID: 16393284
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Higher efficacy of sequential therapy with interferon-alpha and lamivudine combination compared to lamivudine monotherapy in HBeAg positive chronic hepatitis B patients.
    Sarin SK; Kumar M; Kumar R; Kazim SN; Guptan RC; Sakhuja P; Sharma BC
    Am J Gastroenterol; 2005 Nov; 100(11):2463-71. PubMed ID: 16279901
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Risk for hepatocellular carcinoma with respect to hepatitis B virus genotypes B/C, specific mutations of enhancer II/core promoter/precore regions and HBV DNA levels.
    Yuen MF; Tanaka Y; Shinkai N; Poon RT; But DY; Fong DY; Fung J; Wong DK; Yuen JC; Mizokami M; Lai CL
    Gut; 2008 Jan; 57(1):98-102. PubMed ID: 17483190
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Selection of precore mutants during lamivudine treatment in patients with chronic hepatitis B.
    Cheong JY; Cho SW; Yoo JH; Hong SP; Kim SO; Yoo WD; Kim JH
    Hepatogastroenterology; 2008; 55(84):1029-33. PubMed ID: 18705323
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Relationship between Shenzhen HBV genotype and precore/core promoter mutation and antiviral effects].
    Yuan J; Zhou BP; Gong ZJ; Xu LM; Jiang XL; Mizokami M
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2006 Mar; 20(1):30-2. PubMed ID: 16642214
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Decreasing serum alpha-fetoprotein levels in predicting poor prognosis of acute hepatic failure in patients with chronic hepatitis B.
    Yang SS; Cheng KS; Lai YC; Wu CH; Chen TK; Lee CL; Chen DS
    J Gastroenterol; 2002; 37(8):626-32. PubMed ID: 12203078
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Determinants of the clinical outcome of patients with severe acute exacerbation of chronic hepatitis B virus infection.
    Mori N; Suzuki F; Kawamura Y; Sezaki H; Hosaka T; Akuta N; Kobayashi M; Saito S; Suzuki Y; Arase Y; Ikeda K; Kobayashi M; Kumada H
    J Gastroenterol; 2012 Sep; 47(9):1022-9. PubMed ID: 22370817
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.